| Year |
Citation |
Score |
| 2023 |
DeGruttola V, Nakazawa M, Lin T, Liu J, Goyal R, Little S, Tu X, Mehta S. Modeling homophily in dynamic networks with application to HIV molecular surveillance. Bmc Infectious Diseases. 23: 656. PMID 37794364 DOI: 10.1186/s12879-023-08598-x |
0.444 |
|
| 2022 |
Lynch ML, DeGruttola V. Ensemble clustering of longitudinal bivariate HIV biomarker profiles to group patients by patterns of disease progression. International Journal of Data Science and Analytics. 1-14. PMID 35528805 DOI: 10.1007/s41060-022-00323-2 |
0.303 |
|
| 2022 |
Magosi LE, Zhang Y, Golubchik T, DeGruttola V, Tchetgen Tchetgen E, Novitsky V, Moore J, Bachanas P, Segolodi T, Lebelonyane R, Pretorius Holme M, Moyo S, Makhema J, Lockman S, Fraser C, et al. Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial - BCPP/Ya Tsie trial. Elife. 11. PMID 35229714 DOI: 10.7554/eLife.72657 |
0.451 |
|
| 2021 |
Little SJ, Chen T, Wang R, Anderson C, Pond SK, Nakazawa M, Mathews WC, DeGruttola V, Smith DM. Effective Human Immunodeficiency Virus Molecular Surveillance Requires Identification of Incident Cases of Infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 73: 842-849. PMID 34492694 DOI: 10.1093/cid/ciab140 |
0.386 |
|
| 2020 |
Molebatsi K, Gabaitiri L, Mokgatlhe L, Moyo S, Gaseitsiwe S, Wirth KE, DeGruttola V, Tchetgen ET. Efficient estimation of human immunodeficiency virus incidence rate using a pooled cross-sectional cohort study design. Statistics in Medicine. 39: 3255-3271. PMID 32875624 DOI: 10.1002/Sim.8661 |
0.479 |
|
| 2020 |
Wirth KE, Gaolathe T, Pretorius Holme M, Mmalane M, Kadima E, Chakalisa U, Manyake K, Matildah Mbikiwa A, Simon SV, Letlhogile R, Mukokomani K, van Widenfelt E, Moyo S, Bennett K, Leidner J, ... ... DeGruttola V, et al. Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial. The Lancet. Hiv. 7: e422-e433. PMID 32504575 DOI: 10.1016/S2352-3018(20)30103-X |
0.499 |
|
| 2020 |
Novitsky V, Zahralban-Steele M, Moyo S, Nkhisang T, Maruapula D, McLane MF, Leidner J, Bennett K, Wirth KE, Gaolathe T, Kadima E, Chakalisa U, Holme MP, Lockman S, Mmalane M, ... ... DeGruttola V, et al. Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages across Villages in Botswana Treatment-as-Prevention Trial. The Journal of Infectious Diseases. PMID 32492145 DOI: 10.1093/Infdis/Jiaa276 |
0.483 |
|
| 2020 |
Wang R, Bing A, Wang C, Hu Y, Bosch RJ, DeGruttola V. A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption. Statistics in Medicine. PMID 32293756 DOI: 10.1002/Sim.8529 |
0.507 |
|
| 2020 |
Bing A, Hu Y, Prague M, Hill AL, Li JZ, Bosch RJ, DeGruttola V, Wang R. Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption Statistical Communications in Infectious Diseases. DOI: 10.1515/Scid-2019-0021 |
0.461 |
|
| 2019 |
Fleming TR, DeGruttola V, Donnell D. Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions. Statistical Communications in Infectious Diseases. 11. PMID 33777327 DOI: 10.1515/Scid-2019-0001 |
0.463 |
|
| 2019 |
Makhema J, Wirth KE, Pretorius Holme M, Gaolathe T, Mmalane M, Kadima E, Chakalisa U, Bennett K, Leidner J, Manyake K, Mbikiwa AM, Simon SV, Letlhogile R, Mukokomani K, van Widenfelt E, ... ... DeGruttola V, et al. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. The New England Journal of Medicine. 381: 230-242. PMID 31314967 DOI: 10.1056/Nejmoa1812281 |
0.507 |
|
| 2019 |
Kobe JB, Talbot O, Chen I, Eshleman SH, Cummings V, Wheeler DP, Mayer KH, DeGruttola V. Viral genetic linkage analysis among Black men who have sex with men (HIV Prevention Trials Network 061). Aids Research and Human Retroviruses. PMID 30638029 DOI: 10.1089/Aid.2018.0204 |
0.487 |
|
| 2017 |
Balzer L, Staples P, Onnela J, DeGruttola V. Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. Clinical Trials. 14: 201-210. PMID 28124579 DOI: 10.1177/1740774516679666 |
0.506 |
|
| 2016 |
Abuelezam NN, McCormick AW, Fussell T, Afriyie AN, Wood R, DeGruttola V, Freedberg KA, Lipsitch M, Seage GR. Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. American Journal of Epidemiology. PMID 27416841 DOI: 10.1093/Aje/Kwv344 |
0.538 |
|
| 2016 |
Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, Yankinda EK, Lei Q, Mmalane M, Novitsky V, Okui L, van Widenfelt E, Powis KM, Khan N, Bennett K, ... ... DeGruttola V, et al. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. The Lancet. Hiv. 3: e221-30. PMID 27126489 DOI: 10.1016/S2352-3018(16)00037-0 |
0.507 |
|
| 2016 |
Prague M, Wang R, Stephens A, Tchetgen Tchetgen E, DeGruttola V. Accounting for interactions and complex inter-subject dependency in estimating treatment effect in cluster-randomized trials with missing outcomes. Biometrics. PMID 27060877 DOI: 10.1111/Biom.12519 |
0.331 |
|
| 2015 |
Wirth KE, Agniel D, Barr CD, Austin MD, DeGruttola V. A composite likelihood approach for estimating HIV prevalence in the presence of spatial variation. Statistics in Medicine. 34: 3750-9. PMID 26215657 DOI: 10.1002/Sim.6589 |
0.522 |
|
| 2015 |
Novitsky V, Bussmann H, Okui L, Logan A, Moyo S, van Widenfelt E, Mmalane M, Lei Q, Holme MP, Makhema J, Lockman S, Degruttola V, Essex M. Estimated age and gender profile of individuals missed by a home-based HIV testing and counselling campaign in a Botswana community. Journal of the International Aids Society. 18: 19918. PMID 26028155 DOI: 10.7448/Ias.18.1.19918 |
0.494 |
|
| 2015 |
Shikuma CM, Bennett K, Ananworanich J, Gerschenson M, Teeratakulpisarn N, Jadwattanakul T, DeGruttola V, McArthur JC, Ebenezer G, Chomchey N, Praihirunkit P, Hongchookiat P, Mathajittiphun P, Nakamoto B, Hauer P, et al. Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. Journal of Neurovirology. PMID 26002840 DOI: 10.1007/S13365-015-0352-0 |
0.456 |
|
| 2015 |
Lynch ML, DeGruttola V. Predicting time to threshold for initiating antiretroviral treatment to evaluate cost of treatment as HIV prevention. Journal of the Royal Statistical Society. Series C, Applied Statistics. 64: 359-375. PMID 25620814 DOI: 10.1111/Rssc.12080 |
0.519 |
|
| 2015 |
Novitsky V, Moyo S, Lei Q, DeGruttola V, Essex M. Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering. Aids Research and Human Retroviruses. 31: 531-42. PMID 25560745 DOI: 10.1089/Aid.2014.0211 |
0.468 |
|
| 2014 |
Novitsky V, Moyo S, Lei Q, DeGruttola V, Essex M. Impact of sampling density on the extent of HIV clustering. Aids Research and Human Retroviruses. 30: 1226-35. PMID 25275430 DOI: 10.1089/Aid.2014.0173 |
0.482 |
|
| 2014 |
Burns DN, DeGruttola V, Pilcher CD, Kretzschmar M, Gordon CM, Flanagan EH, Duncombe C, Cohen MS. Toward an endgame: finding and engaging people unaware of their HIV-1 infection in treatment and prevention. Aids Research and Human Retroviruses. 30: 217-24. PMID 24410300 DOI: 10.1089/Aid.2013.0274 |
0.517 |
|
| 2014 |
Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JLK, Marovich MA, ... ... DeGruttola V, et al. Correction: HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients (PLoS ONE) Plos One. 9. DOI: 10.1371/Annotation/18C308Ec-1Cff-4E93-B4Bb-6C9Fc3A25A15 |
0.351 |
|
| 2013 |
Novitsky V, Bussmann H, Logan A, Moyo S, van Widenfelt E, Okui L, Mmalane M, Baca J, Buck L, Phillips E, Tim D, McLane MF, Lei Q, Wang R, Makhema J, ... ... DeGruttola V, et al. Phylogenetic relatedness of circulating HIV-1C variants in Mochudi, Botswana. Plos One. 8: e80589. PMID 24349005 DOI: 10.1371/Journal.Pone.0080589 |
0.504 |
|
| 2013 |
Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JL, Marovich MA, ... ... DeGruttola V, et al. HIV DNA reservoir increases risk for cognitive disorders in cART-naïve patients. Plos One. 8: e70164. PMID 23936155 DOI: 10.1371/Journal.Pone.0070164 |
0.459 |
|
| 2013 |
Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, Tipsuk S, Fletcher JL, Degruttola V, Ratto-Kim S, Hutchings N, Shikuma C, Ananworanich J. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. Journal of Neurovirology. 19: 137-43. PMID 23483520 DOI: 10.1007/S13365-013-0151-4 |
0.425 |
|
| 2013 |
Stock S, DeGruttola V. Recursive partitioning for monotone missing at random longitudinal markers. Statistics in Medicine. 32: 978-94. PMID 22941582 DOI: 10.1002/Sim.5574 |
0.488 |
|
| 2012 |
Sailasuta N, Ross W, Ananworanich J, Chalermchai T, DeGruttola V, Lerdlum S, Pothisri M, Busovaca E, Ratto-Kim S, Jagodzinski L, Spudich S, Michael N, Kim JH, Valcour V. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. Plos One. 7: e49272. PMID 23229129 DOI: 10.1371/Journal.Pone.0049272 |
0.484 |
|
| 2012 |
Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Paul R, Kallianpur K, Chow D, Gavegnano C, Hurwitz SJ, Schinazi RF, Valcour VG. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antiviral Therapy. 17: 1233-42. PMID 23018140 DOI: 10.3851/Imp2411 |
0.459 |
|
| 2012 |
Yang Y, DeGruttola V. Resampling-based methods in single and multiple testing for equality of covariance/correlation matrices. The International Journal of Biostatistics. 8: 1-32. PMID 22740584 DOI: 10.1515/1557-4679.1388 |
0.38 |
|
| 2012 |
Shikuma CM, Gerschenson M, Ananworanich J, Valcour VG, Teeratakulpisarn N, Jadwattanakul T, Degruttola V, Liang CY, McArthur JC, Ebenezer GJ, Chomchey N, Praihirunkit P, Hongchookiath P, Mathajittiphun P, Nakamoto B, et al. Determinants of epidermal nerve fibre density in antiretroviral-naïve HIV-infected individuals Hiv Medicine. 13: 602-608. PMID 22574621 DOI: 10.1111/J.1468-1293.2012.01024.X |
0.445 |
|
| 2012 |
Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG. Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial. Aids Research and Human Retroviruses. 28: 759-65. PMID 22540188 DOI: 10.1089/Aid.2011.0303 |
0.314 |
|
| 2012 |
Goyal R, Wang R, DeGruttola V. Editorial commentary: network epidemic models: assumptions and interpretations. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 276-8. PMID 22491502 DOI: 10.1093/Cid/Cis388 |
0.35 |
|
| 2012 |
Lok JJ, DeGruttola V. Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients. Biometrics. 68: 745-54. PMID 22352840 DOI: 10.1111/J.1541-0420.2011.01738.X |
0.476 |
|
| 2012 |
Wester CW, Stitelman OM, deGruttola V, Bussmann H, Marlink RG, van der Laan MJ. Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. Aids Research and Human Retroviruses. 28: 981-8. PMID 22309114 DOI: 10.1089/Aid.2011.0349 |
0.342 |
|
| 2012 |
Hogan CM, Degruttola V, Sun X, Fiscus SA, Del Rio C, Hare CB, Markowitz M, Connick E, MacAtangay B, Tashima KT, Kallungal B, Camp R, Morton T, Daar ES, Little S. The setpoint study (ACTG A5217): Effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals Journal of Infectious Diseases. 205: 87-96. PMID 22180621 DOI: 10.1093/Infdis/Jir699 |
0.515 |
|
| 2012 |
Shikuma CM, Seto T, Liang CY, Bennett K, DeGruttola V, Gerschenson M, Stein JH, Budoff M, Hodis HN, Delaney JA, Ogata-Arakaki D, Pramyothin P, Chow D. Vitamin D levels and markers of arterial dysfunction in HIV. Aids Research and Human Retroviruses. 28: 793-7. PMID 21978287 DOI: 10.1089/Aid.2011.0086 |
0.413 |
|
| 2011 |
Merchant RC, Clark MA, Langan TJ, Mayer KH, Seage GR, DeGruttola VG. Can computer-based feedback improve emergency department patient uptake of rapid HIV screening? Annals of Emergency Medicine. 58: S114-9.e1-2. PMID 21684389 DOI: 10.1016/J.Annemergmed.2011.03.035 |
0.396 |
|
| 2011 |
Hu C, Degruttola V. Recursive partitioning of resistant mutations for longitudinal markers based on a U-type score. Biostatistics (Oxford, England). 12: 750-62. PMID 21596729 DOI: 10.1093/Biostatistics/Kxr011 |
0.355 |
|
| 2011 |
DeGruttola V, Schooley RT. Antiretroviral therapy as prevention: linking the mainframe to Main Street. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 52: 1050-2. PMID 21460323 DOI: 10.1093/Cid/Cir094 |
0.31 |
|
| 2011 |
Gilbert PB, Berger JO, Stablein D, Becker S, Essex M, Hammer SM, Kim JH, Degruttola VG. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. The Journal of Infectious Diseases. 203: 969-75. PMID 21402548 DOI: 10.1093/Infdis/Jiq152 |
0.326 |
|
| 2011 |
Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D. Implications of HIV PrEP trials results. Aids Research and Human Retroviruses. 27: 81-90. PMID 20969483 DOI: 10.1089/Aid.2010.0226 |
0.449 |
|
| 2010 |
Kolber MA, Buendia P, Degruttola V, Moore RD. HIV-1 diversity after a class switch failure. Aids Research and Human Retroviruses. 26: 1175-80. PMID 20854203 DOI: 10.1089/Aid.2010.0069 |
0.317 |
|
| 2010 |
Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, Wester CW, Ogwu A, Asmelash A, Musonda R, Campa A, Moyo S, van Widenfelt E, ... ... DeGruttola V, et al. HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. Plos One. 5: e10148. PMID 20405044 DOI: 10.1371/Journal.Pone.0010148 |
0.538 |
|
| 2010 |
DeGruttola V, Smith DM, Little SJ, Miller V. Developing and evaluating comprehensive HIV infection control strategies: issues and challenges. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 50: S102-7. PMID 20397937 DOI: 10.1086/651480 |
0.509 |
|
| 2010 |
Merchant RC, Freelove SM, Langan TJ, Clark MA, Mayer KH, Seage GR, DeGruttola VG. The relationship of reported HIV risk and history of HIV testing among emergency department patients. Postgraduate Medicine. 122: 61-74. PMID 20107290 DOI: 10.3810/Pgm.2010.01.2100 |
0.421 |
|
| 2010 |
Wester CW, Thomas AM, Bussmann H, Moyo S, Makhema JM, Gaolathe T, Novitsky V, Essex M, deGruttola V, Marlink RG. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. Aids (London, England). 24: S27-36. PMID 20023437 DOI: 10.1097/01.Aids.0000366080.91192.55 |
0.341 |
|
| 2010 |
Tournoud M, Etard JF, Ecochard R, DeGruttola V. Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort. Statistics in Medicine. 29: 14-32. PMID 19941299 DOI: 10.1002/Sim.3779 |
0.333 |
|
| 2010 |
Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D. Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. Aids (London, England). 24: 365-71. PMID 19864933 DOI: 10.1097/Qad.0B013E32833338Ba |
0.457 |
|
| 2009 |
Merchant RC, Clark MA, Langan TJ, Seage GR, Mayer KH, DeGruttola VG. Effectiveness of increasing emergency department patients' self-perceived risk for being human immunodeficiency virus (HIV) infected through audio computer self-interview-based feedback about reported HIV risk behaviors. Academic Emergency Medicine : Official Journal of the Society For Academic Emergency Medicine. 16: 1143-55. PMID 20053235 DOI: 10.1111/J.1553-2712.2009.00537.X |
0.322 |
|
| 2009 |
Buendia P, Cadwallader B, DeGruttola V. A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics (Oxford, England). 25: 2522-9. PMID 19654117 DOI: 10.1093/Bioinformatics/Btp466 |
0.385 |
|
| 2009 |
Merchant RC, Catanzaro BM, Seage GR, Mayer KH, Clark MA, Degruttola VG, Becker BM. Demographic variations in HIV testing history among emergency department patients: implications for HIV screening in US emergency departments. Journal of Medical Screening. 16: 60-6. PMID 19564517 DOI: 10.1258/Jms.2009.008058 |
0.433 |
|
| 2009 |
Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, Siangphoe U, Kim JH, De Souza M, Degruttola V, Paul RH, Shikuma CM. HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: The SEARCH 001 Cohort study Neurology. 72: 992-998. PMID 19289739 DOI: 10.1212/01.Wnl.0000344404.12759.83 |
0.485 |
|
| 2009 |
Merchant RC, Clark MA, Seage GR, Mayer KH, Degruttola VG, Becker BM. Emergency department patient perceptions and preferences on opt-in rapid HIV screening program components. Aids Care. 21: 490-500. PMID 19283644 DOI: 10.1080/09540120802270284 |
0.35 |
|
| 2009 |
Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, ... ... Degruttola V, et al. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. Journal of Acquired Immune Deficiency Syndromes (1999). 51: 37-46. PMID 19282782 DOI: 10.1097/Qai.0B013E31819Ff102 |
0.507 |
|
| 2009 |
Merchant RC, Clark MA, Mayer KH, Seage Iii GR, DeGruttola VG, Becker BM. Video as an effective method to deliver pretest information for rapid human immunodeficiency testing. Academic Emergency Medicine : Official Journal of the Society For Academic Emergency Medicine. 16: 124-35. PMID 19120050 DOI: 10.1111/J.1553-2712.2008.00326.X |
0.338 |
|
| 2009 |
DeGruttola V, Little S, Schooley R. Controlling the HIV epidemic, without a vaccine! Aids (London, England). 22: 2554-5. PMID 19005285 DOI: 10.1097/Qad.0B013E32831940D3 |
0.418 |
|
| 2008 |
Schumi J, DiRienzo AG, DeGruttola V. Testing for associations with missing high-dimensional categorical covariates. The International Journal of Biostatistics. 4: Article 18. PMID 20231909 DOI: 10.2202/1557-4679.1102 |
0.397 |
|
| 2008 |
Merchant RC, Seage GR, Mayer KH, Clark MA, DeGruttola VG, Becker BM. Emergency department patient acceptance of opt-in, universal, rapid HIV screening. Public Health Reports (Washington, D.C. : 1974). 123: 27-40. PMID 19172704 DOI: 10.1177/00333549081230S305 |
0.357 |
|
| 2008 |
Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. The Journal of Infectious Diseases. 198: 470-80. PMID 18598191 DOI: 10.1086/590156 |
0.4 |
|
| 2008 |
Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. Hiv Clinical Trials. 9: 11-25. PMID 18215978 DOI: 10.1310/Hct0901-11 |
0.498 |
|
| 2008 |
Schumi J, DeGruttola V. Resampling-based analyses of the effects of combinations of HIV genetic mutations on drug susceptibility. Statistics in Medicine. 27: 4740-4757. PMID 18186529 DOI: 10.1002/Sim.3181 |
0.417 |
|
| 2008 |
Yang Y, DeGruttola V. Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility. Biometrics. 64: 329-336. PMID 17900313 DOI: 10.1111/J.1541-0420.2007.00883.X |
0.487 |
|
| 2007 |
Vaida F, Fitzgerald AP, DeGruttola V. Efficient hybrid EM for linear and nonlinear mixed effects models with censored response Computational Statistics & Data Analysis. 51: 5718-5730. PMID 19578533 DOI: 10.1016/J.Csda.2006.09.036 |
0.38 |
|
| 2007 |
Merchant RC, Gee EM, Clark MA, Mayer KH, Seage GR, Degruttola VG. Comparison of patient comprehension of rapid HIV pre-test fundamentals by information delivery format in an emergency department setting. Bmc Public Health. 7: 238. PMID 17850670 DOI: 10.1186/1471-2458-7-238 |
0.352 |
|
| 2007 |
Novitsky V, Wester CW, DeGruttola V, Bussmann H, Gaseitsiwe S, Thomas A, Moyo S, Musonda R, Van Widenfelt E, Marlink RG, Essex M. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. Aids Research and Human Retroviruses. 23: 868-78. PMID 17678469 DOI: 10.1089/Aid.2006.0298 |
0.48 |
|
| 2007 |
May S, Degruttola V. Nonparametric tests for two-group comparisons of dependent observations obtained at varying time points. Biometrics. 63: 194-200. PMID 17447945 DOI: 10.1111/J.1541-0420.2006.00676.X |
0.355 |
|
| 2007 |
Healy B, Degruttola V. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses Biostatistics. 8: 438-452. PMID 16940036 DOI: 10.1093/Biostatistics/Kxl021 |
0.484 |
|
| 2007 |
Merchant R, Mayer K, Seage G, Clark M, Degruttola V, Becker B. Is a 9.5 Minute Video an Effective Substitute for an HIV Counselor for Rapid HIV Testing Academic Emergency Medicine. 14. DOI: 10.1197/J.Aem.2007.03.1206 |
0.512 |
|
| 2006 |
Kassutto S, Maghsoudi K, Johnston MN, Robbins GK, Burgett NC, Sax PE, Cohen D, Pae E, Davis B, Zachary K, Basgoz N, D'agata EM, DeGruttola V, Walker BD, Rosenberg ES. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 42: 1024-31. PMID 16511771 DOI: 10.1086/500410 |
0.458 |
|
| 2004 |
Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A. Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. The Journal of Infectious Diseases. 189: 1811-20. PMID 15122517 DOI: 10.1086/383277 |
0.353 |
|
| 2003 |
Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antiviral Therapy. 8: 507-18. PMID 14760884 |
0.4 |
|
| 2003 |
Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, DeGruttola V. Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options The Journal of Infectious Diseases. 188: 1001-1008. PMID 14513420 DOI: 10.1086/378355 |
0.394 |
|
| 2003 |
DiRienzo AG, DeGruttola V, Larder B, Hertogs K. Non-parametric methods to predict HIV drug susceptibility phenotype from genotype. Statistics in Medicine. 22: 2785-98. PMID 12939786 DOI: 10.1002/Sim.1516 |
0.433 |
|
| 2003 |
Foulkes AS, DeGruttola V. Characterizing classes of antiretroviral drugs by genotype. Statistics in Medicine. 22: 2637-55. PMID 12898549 DOI: 10.1002/Sim.1465 |
0.401 |
|
| 2003 |
DiRienzo AG, DeGruttola V. Design and analysis of clinical trials with a bivariate failure time endpoint, with application to AIDS Clinical Trials Group Study A5142. Controlled Clinical Trials. 24: 122-34. PMID 12689734 DOI: 10.1016/S0197-2456(02)00321-5 |
0.444 |
|
| 2002 |
Bennett KK, DeGruttola VG, Marschner IC, Havlir DV, Richman DD. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy Journal of Acquired Immune Deficiency Syndromes. 31: 20-26. PMID 12352146 DOI: 10.1097/00126334-200209010-00003 |
0.314 |
|
| 2002 |
Fitzgerald AP, DeGruttola VG, Vaida F. Modelling HIV viral rebound using non-linear mixed effects models Statistics in Medicine. 21: 2093-2108. PMID 12111889 DOI: 10.1002/Sim.1155 |
0.462 |
|
| 2002 |
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, ... ... DeGruttola V, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Jama. 288: 169-80. PMID 12095381 DOI: 10.1001/Jama.288.2.169 |
0.331 |
|
| 2002 |
Kowalski J, Pagano M, DeGruttola V. A Nonparametric Test of Gene Region Heterogeneity Associated with Phenotype Journal of the American Statistical Association. 97: 398-408. DOI: 10.1198/016214502760046952 |
0.335 |
|
| 2001 |
Smeaton LM, DeGruttola V, Robbins GK, Shafer RW. ACTG (AIDS Clinical Trials Group) 384: A Strategy Trial Comparing Consecutive Treatments for HIV-1 Controlled Clinical Trials. 22: 142-159. PMID 11306153 DOI: 10.1016/S0197-2456(00)00126-4 |
0.443 |
|
| 2001 |
Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. Jama. 285: 777-784. PMID 11176916 DOI: 10.1001/Jama.285.6.777 |
0.434 |
|
| 2000 |
Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, ... ... deGruttola V, et al. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. The Journal of Infectious Diseases. 182: 1357-64. PMID 11023459 DOI: 10.1086/315860 |
0.493 |
|
| 2000 |
Babiker A, Bartlett J, Breckenridge A, Collins G, Coombs R, Cooper D, Creagh T, Cross A, Daniels M, Darbyshire J, Dawson D, DeGruttola V, DeMasi R, Dolin R, Eron J, et al. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis Aids Research and Human Retroviruses. 16: 1123-1133. PMID 10954887 DOI: 10.1089/088922200414965 |
0.398 |
|
| 2000 |
Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, Boucher CA. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. The Journal of Infectious Diseases. 182: 59-67. PMID 10882582 DOI: 10.1086/315673 |
0.421 |
|
| 2000 |
Kim S, Hughes MD, Hammer SM, Jackson JB, DeGruttola V, Katzenstein DA. Both Serum HIV Type 1 RNA Levels and CD4+ Lymphocyte Counts Predict Clinical Outcome in HIV Type 1-Infected Subjects with 200 to 500 CD4+ Cells per Cubic Millimeter Aids Research and Human Retroviruses. 16: 645-653. PMID 10791875 DOI: 10.1089/088922200308873 |
0.471 |
|
| 1999 |
Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: Statistical analysis and potential biases Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 20: 220-227. PMID 10077169 DOI: 10.1097/00042560-199903010-00002 |
0.512 |
|
| 1999 |
Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR. Treatment with Amprenavir Alone or Amprenavir with Zidovudine and Lamivudine in Adults with Human Immunodeficiency Virus Infection The Journal of Infectious Diseases. 179: 808-816. PMID 10068575 DOI: 10.1086/314668 |
0.502 |
|
| 1998 |
Gilbert P, DeGruttola V, Hammer S. Efficient Trial Designs for Studying Combination Antiretroviral Treatments in Patients with Various Resistance Profiles The Journal of Infectious Diseases. 178: 340-348. PMID 9697713 DOI: 10.1086/515647 |
0.335 |
|
| 1998 |
Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. The Journal of Infectious Diseases. 177: 40-7. PMID 9419168 DOI: 10.1086/513823 |
0.508 |
|
| 1996 |
Cohen CJ, Hellinger JA, Day J, Salitsky N, Shevitz A, Zackin R, DeGruttola V. Lack of Effect of Cimetidine on Lymphocyte Subsets in Patients Infected with Human Immunodeficiency Virus Type 1 Clinical Infectious Diseases. 23: 1049-1054. PMID 8922801 DOI: 10.1093/Clinids/23.5.1049 |
0.454 |
|
| 1996 |
Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, Degruttola V, Crumpacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection Journal of Infectious Diseases. 174: 704-712. PMID 8843206 DOI: 10.1093/Infdis/174.4.704 |
0.503 |
|
| 1995 |
D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Annals of Internal Medicine. 122: 401-8. PMID 7856987 DOI: 10.7326/0003-4819-122-6-199503150-00001 |
0.489 |
|
| 1995 |
Ragni M, Amato D, LoFaro M, DeGruttola V, Horst CVD, Eyster M, Kessler C, Gjerset G, Ho M, Parenti D. Randomized study of didanosine monotherapy and combination therapy with zidovudine in hemophilic and nonhemophilic subjects with asymptomatic human immunodeficiency virus-1 infection. AIDS Clinical Trial Groups. Blood. 85: 2337-2346. DOI: 10.1182/Blood.V85.9.2337.Bloodjournal8592337 |
0.41 |
|
| 1995 |
Tsiatis AA, Degruttola V, Wulfsohn MS. Modeling the relationship of survival to longitudinal data measured with error. Applications to survival and cd4 counts in patients with aids Journal of the American Statistical Association. 90: 27-37. DOI: 10.1080/01621459.1995.10476485 |
0.364 |
|
| 1994 |
DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. The Journal of Infectious Diseases. 169: 713-21. PMID 8133085 DOI: 10.1093/Infdis/169.4.713 |
0.363 |
|
| 1994 |
Gauvreau K, Degruttola V, Pagano M, Bellocco R. The effect of covariates on the induction time of AIDS using improved imputation of exact seroconversion times Statistics in Medicine. 13: 2021-2030. PMID 7846407 DOI: 10.1002/Sim.4780131912 |
0.408 |
|
| 1992 |
Degruttola V, Tu XM, Pagano M. Pediatric AIDS in New York City: Estimating the Distributions of Infection, Latency, and Reporting Delay and Projecting Future Incidence Journal of the American Statistical Association. 87: 633-640. DOI: 10.1080/01621459.1992.10475262 |
0.388 |
|
| 1991 |
Degruttola V, Lange N, Dafni U. Modeling the Progression of HIV Infection Journal of the American Statistical Association. 86: 569-577. DOI: 10.1080/01621459.1991.10475081 |
0.493 |
|
| 1989 |
DeGruttola V, Seage GR, Mayer KH, Horsburgh CR. Infectiousness Of Hiv Between Male Homosexual Partners Journal of Clinical Epidemiology. 42: 849-856. PMID 2789269 DOI: 10.1016/0895-4356(89)90098-X |
0.447 |
|
| 1987 |
Mayer KH, Degruttola V. Human Immunodeficiency Virus and Oral Intercourse Annals of Internal Medicine. 107: 428-429. PMID 3619236 DOI: 10.7326/0003-4819-107-2-428_2 |
0.424 |
|
| Show low-probability matches. |